21 CFR 211.22
Responsibilities of quality control unit.
- Inspections citing it: 3,470
- Of those classified, ended OAI: 28%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.22(d)
- 2,413 · Procedures not in writing, fully followed
- 211.22(a)
- 818 · Lack of quality control unit
- 211.22(c)
- 174 · Approve or reject procedures or specs
- 211.22(b)
- 65 · Adequate lab facilities not available
Regulation Text
eCFR, as of Nov 6, 2026(a) There shall be a quality control unit that shall have the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated. The quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company.
(b) Adequate laboratory facilities for the testing and approval (or rejection) of components, drug product containers, closures, packaging materials, in-process materials, and drug products shall be available to the quality control unit.
(c) The quality control unit shall have the responsibility for approving or rejecting all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product.
(d) The responsibilities and procedures applicable to the quality control unit shall be in writing; such written procedures shall be followed.
Recently Cited Sites
Newest inspections citing this section; each opens the site- Baxter Healthcare CorporationUnited States · Sep 23, 2026
- PD-Rx Pharmaceuticals, Inc.United States · Aug 20, 2026
- AVEVA Drug Delivery Systems, Inc.United States · Aug 14, 2026
- A-S Medication Solutions LLCUnited States · Aug 12, 2026
- Mountainside Medical Equipment, Inc.United States · Aug 12, 2026
- I. Shay Cosmetics IncUnited States · Jul 17, 2026
- The Flower Remedy LLCUnited States · Jun 12, 2026
- My CHS Rx, Inc.United States · Jun 5, 2026
- Topical Pharmaceuticals, Inc.United States · May 7, 2026
- ProRx LLCUnited States · Sep 19, 2025
- Unilever Manufacturing (US), Inc.United States · Sep 15, 2025
- IntegraDose Compounding Services LLCUnited States · Jul 25, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR